{"nctId":"NCT03594747","briefTitle":"A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer","startDateStruct":{"date":"2018-07-30","type":"ACTUAL"},"conditions":["Non-Small Cell Lung Cancer"],"count":360,"armGroups":[{"label":"Tislelizumab + Paclitaxel + Carboplatin","type":"EXPERIMENTAL","interventionNames":["Drug: Tislelizumab","Drug: Paclitaxel","Drug: Carboplatin"]},{"label":"Tislelizumab + Nab-paclitaxel + Carboplatin","type":"EXPERIMENTAL","interventionNames":["Drug: Tislelizumab","Drug: Nab-paclitaxel","Drug: Carboplatin"]},{"label":"Paclitaxel + Carboplatin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Paclitaxel","Drug: Carboplatin"]}],"interventions":[{"name":"Tislelizumab","otherNames":["BGB-A317","Tevimbra"]},{"name":"Paclitaxel","otherNames":[]},{"name":"Nab-paclitaxel","otherNames":[]},{"name":"Carboplatin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n1. Age 18-75 years old, male or female, and signed informed consent form (ICF)\n2. Advanced NSCLC diagnosed by pathological or clinical physicians\n3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 1\n4. Participants must have ≥ 1 measurable lesion as defined per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\n5. Must be treatment-naive for locally advanced or metastatic squamous NSCLC\n6. Life expectancy ≥ 12 weeks\n7. Participants must have adequate organ function\n8. Male/Female is willing to use a highly effective method of birth control\n\nKey Exclusion Criteria:\n\n1. Diagnosed with NSCLC but with epidermal growth factor receptors (EGFR)-sensitizing mutation or anaplastic lymphoma kinase (ALK) gene translocation\n2. Received any approved systemic anticancer therapy\n3. Received prior treatment with EGFR inhibitors or ALK inhibitors\n4. Received prior therapies targeting programmed death 1 (PD-1) or programmed death ligand 1 (PD-L1)\n5. With history of interstitial lung disease\n6. Clinically significant pericardial effusion\n7. Severe infections, active leptomeningeal disease or uncontrolled, untreated brain metastasis\n8. Any major surgical procedure before randomization\n9. Human immunodeficiency virus infection\n10. Untreated hepatitis B virus (HBV)/hepatitis C virus (HCV)\n11. Active autoimmune diseases or history of autoimmune diseases\n12. History of allergic reactions to chemotherapy\n\nNOTE: Other protocol defined Inclusion/Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression Free Survival (PFS) by Independent Review Committee (IRC) Assessment as of Data Cut-off Date of 06DEC2019","description":"PFS is defined as the time from randomization until first documentation of disease progression as assessed by the IRC per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or death from any cause, whichever occurs first","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.6","spread":null},{"groupId":"OG001","value":"7.6","spread":null},{"groupId":"OG002","value":"5.5","spread":null}]}]}]},{"type":"PRIMARY","title":"PFS by IRC Assessment as of Data Cut-off Date of 30SEP2020","description":"PFS is defined as the time from randomization until first documentation of disease progression as assessed by the IRC per RECIST v1.1 or death from any cause, whichever occurs first","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.7","spread":null},{"groupId":"OG001","value":"9.6","spread":null},{"groupId":"OG002","value":"5.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS is defined as the time from randomization until the date of death due to any cause","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.1","spread":null},{"groupId":"OG001","value":"23.3","spread":null},{"groupId":"OG002","value":"19.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Objective Response Rate (ORR) by IRC Assessment","description":"ORR is defined as the percentage of participants with complete response (CR) and partial response (PR), as assessed by the IRC using RECIST v1.1.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.2","spread":null},{"groupId":"OG001","value":"73.9","spread":null},{"groupId":"OG002","value":"47.9","spread":null}]}]}]},{"type":"SECONDARY","title":"ORR by Investigator Assessment","description":"ORR is defined as the percentage of participants with complete response (CR) and partial response (PR), as assessed by the investigator using RECIST v1.1.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.0","spread":null},{"groupId":"OG001","value":"78.2","spread":null},{"groupId":"OG002","value":"49.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DOR) by IRC Assessment","description":"DOR is defined as the time from the first occurrence of a documented objective response to the time of documented disease progression assessed by the IRC using RECIST v1.1, or death from any cause, whichever comes first, in all randomized participants with documented objective responses. Data are based on number of responders.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.4","spread":null},{"groupId":"OG001","value":"8.6","spread":null},{"groupId":"OG002","value":"4.3","spread":null}]}]}]},{"type":"SECONDARY","title":"DOR by Investigator Assessment","description":"DOR is defined as the time from the first occurrence of a documented objective response to the time of documented disease progression assessed by the investigator using RECIST v1.1, or death from any cause, whichever comes first, in all randomized participants with documented objective responses. Data are based on number of responders.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.6","spread":null},{"groupId":"OG001","value":"8.8","spread":null},{"groupId":"OG002","value":"4.8","spread":null}]}]}]},{"type":"SECONDARY","title":"PFS by Investigator Assessment","description":"PFS is defined as the time from randomization until first documentation of disease progression as assessed by the investigator per RECIST v1.1 or death from any cause, whichever occurs first","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.6","spread":null},{"groupId":"OG001","value":"9.8","spread":null},{"groupId":"OG002","value":"5.5","spread":null}]}]}]},{"type":"SECONDARY","title":"PFS by IRC Based on Programmed Death Ligand 1 (PD-L1) Expression","description":"PFS is defined as the time from randomization until first documentation of disease progression as assessed by the IRC per RECIST v1.1 or death from any cause, whichever occurs first, based on PD-L1 expression in tumor cells","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.6","spread":null},{"groupId":"OG001","value":"7.6","spread":null},{"groupId":"OG002","value":"5.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.9","spread":null},{"groupId":"OG001","value":"9.8","spread":null},{"groupId":"OG002","value":"5.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.7","spread":null},{"groupId":"OG001","value":"9.7","spread":null},{"groupId":"OG002","value":"5.5","spread":null}]}]}]},{"type":"SECONDARY","title":"European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer (EORTC QLQ-LC13)","description":"Least squares mean change from baseline in EORTC QLQ-CL13 scores for chest pain, coughing, and dyspnea between tislelizumab arms and paclitaxel + carboplatin arm. The EORTC QLQ-LC13 is a questionnaire that measures lung cancer-specific disease and treatment symptoms. It includes questions about specific symptoms in which participants respond based on a 4-point scale, where 1 is \"not at all\" and 4 is \"very much\". Raw scores are transformed into a 0 to 100 scale via linear transformation. A lower score indicates an improvement in symptoms.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null},{"groupId":"OG001","value":"-0.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.0","spread":null},{"groupId":"OG001","value":"-0.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.7","spread":null},{"groupId":"OG001","value":"-1.0","spread":null}]}]}]},{"type":"SECONDARY","title":"European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status","description":"Least squares mean change from baseline in EORTC QLQ-C30 Global Health Status/Quality of Life score between tislelizumab arms and paclitaxel + carboplatin arm. The EORTC QLQ-C30 v3.0 is a questionnaire that assesses quality of life of cancer patients. It includes global health status and quality of life questions related to overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. A higher score indicates better health outcomes.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":null},{"groupId":"OG001","value":"3.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events","description":"Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), which includes laboratory tests, physical exams, electrocardiogram results and vital signs, according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"120","spread":null},{"groupId":"OG001","value":"117","spread":null},{"groupId":"OG002","value":"117","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"55","spread":null},{"groupId":"OG002","value":"29","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":56,"n":120},"commonTop":["Anaemia","Alopecia","Neutrophil count decreased","White blood cell count decreased","Leukopenia"]}}}